Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Trial Profile

First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs CMX-521 (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 08 Nov 2018 According to a Chimerix media release, results for this trial were presented in a financial report
    • 08 Nov 2018 According to a Chimerix media release, data from this trial was presented data on CMX521 at the European Society for Clinical Virology in Athens, Greece
    • 08 Aug 2018 According to a Chimerix media release, the first presentation of clinical data on CMX521 will be in September at the European Society for Clinical Virology in Athens, Greece.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top